Feb 11 2015
ReportsnReports.com adds Global & USA Transdermal Drug Delivery Market to 2020: Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and SWOT Investigation research report to its store.
This comprehensive transdermal drug delivery industry report tackles problems that this vertical growing market faces and evaluates saturated sub-markets. A detailed outlay of its major players is performed including business strategy and future development analysis, merger and acquisition tactics, current product and pipeline entry evaluation and a detailed section on each player's financial situation. This analysis determines the unmet needs of the transdermal drug delivery industry and specific niche areas of market entry. The transdermal drug delivery market has substantial associations within the smoking cessation market, analgesics/pain market, generics market, neuropathic pain market and also the women's health market. In the future it will enter the vaccine and gene therapy markets. Transdermal drug delivery is a complex area that has many driving factors including the unmet need for non-invasive drug delivery systems for pediatric, geriatric and dementia patients. Complete research is available at http://www.reportsnreports.com/reports/344208-global-transdermal-drug-delivery-market-to-2017.html .
This transdermal drug delivery market report describes the current technologies that are propelling the market space and emerging trials and pipeline agents that will make a significant impact on the industry. It examines the current transdermal delivery systems and how generic competition is allowing penetration of new players in the market and saturation of niche areas. Financial figures of the drug delivery market and the transdermal drug delivery space are revealed in this report. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial, business strategy and product review of key players in the transdermal drug delivery industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.
In summary, the transdermal drug delivery market has huge opportunities for growth in the areas of dementia (Alzheimer's & Parkinson 's disease), generics, paediatrics and geriatrics. Currently the USA is the most prominent market place, followed by Europe, Asia and Emerging Markets. This report will reveal in-depth analysis of the industry and provide cutting-edge intelligence on the current and future spaces it will penetrate.
The transdermal drug delivery industry report is supported by 320 tables & figures over 280 pages. This report is presented as follows:
By Company (e.g., JANSSEN, MYLAN, ACTAVIS, GLAXOSMITHKLINE, BAYER, NOVARTIS, NOVEN, LAVIPHARM, PROSTRACKEN, NITTO DENTO)
By Geography (Global, USA)
By Parent Market (Drug Delivery Systems, Advanced Drug Delivery Systems)
By Sub-market (Generics, Women's Health, Analgesics, Neuropathic Pain)
Companies discussed in this transdermal drug delivery research report include Actavis, Actelion, GlaxoSmithKline, Bayer, Mylan Pharmaceuticals, Novartis, Upsher-Smith, Ascend Therapeutics, AMAG Pharmaceuticals (Lumara Health, KV Pharm/Ther-Rx Corp), Janssen Pharmaceuticals, Noven Pharmaceuticals, ProStrakan, Shire, Hercon Pharmaceutical, Kremers Urban Pharmaceuticals, Nitto Denko, Teva Pharmaceutical Industries, Endo International, Teikoku USA, Boehringer Ingelheim, 3M, UCB and ParPharm. Order a copy of this research at http://www.reportsnreports.com/Purchase.aspx?name=344208 .
The bestselling transdermal systems include narcotic analgesics, antihypertensives, Alzheimer's disease agents, hormone replacement patches within women's healthcare and nicotine patches for smoking cessation. Top products within the TDDM include Lidoderm, Duragesic/fentanyl drug delivery system and Exelon. TDS technology has to date been applied to a variety of indications, most recently Migraine, Dementia, Parkinson's Disease, Depression, ADHD, Chronic Pain and Overactive Bladder. This research forecasts that other neurodegenerative and progressive disorders such as Parkinson's Disease (PD) will become key indications for TDD in the near future once approvals are granted. Currently a number of companies are in the process of trialling rotigotine, lisuride and apomorphine TDD systems for Parkinson's and Restless Leg Syndrome (RLS) patients.
This report also delves into key characterization tools that are required to evaluate the performance of transdermal systems. One of the most important investigating tools is in vitro drug releasing tests including the static Franz diffusion cell and side-bi-side cells. Commercially available skin models include MatTek's patented EpiDerm™ System which consists of normal, human-derived epidermal keratinocytes (NHEK) which have been cultured to form a multilayered, highly differentiated model of the human epidermis.
The use of nanotechnology applications for the transdermal drug delivery market is having a positive impact on the space and key players within this niche market include GlaxoSmithKline, Aphios, and Protiva. To date nanoparticles, nanoemulsions and nanopatches are all leading the way. Current studies are examining the use of stable nucleic acids such as siRNA and aptamers in tumor biology and also viral antigens within HIV vaccine studies.
Source: http://www.reportsnreports.com